2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
January 21st, 2025
Version: 2
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Scien1ces, University of Copenhagen, Copenhagen, Denmark, and Max Planck Inst
cancer biology
biorxiv

In depth profiling of the cancer proteome from the flowthrough of standard RNA-preparation kits for precision oncology

Mundt Madsen, F.Open in Google Scholar•Nielsen, A. B.Open in Google Scholar•Wang, J.Open in Google Scholar•Duel, J. K.Open in Google Scholar•Yde, C. W.Open in Google Scholar•Eriksen, M. A.Open in Google Scholar•Lassen, U.Open in Google Scholar•Nielsen, F. C.Open in Google Scholar•Rohrberg, K.Open in Google Scholar•Mann, M.Open in Google Scholar

Cancer is a highly heterogeneous disease, even within the same patient. Biopsies taken from different regions of a tumor may stand in stark molecular contrast to each other. Therefore, the ability to generate meaningful data from multiple platforms using the same biopsy is crucial for translating multi-omics characterizations into the clinic. However, it is generally a cumbersome and lengthy procedure to generate DNA, RNA and protein material from the same biopsy. The Qiagen AllPrep kit is an accessible, straightforward, and widely used kit in clinics worldwide to process biopsies and generate genomic and transcriptomic data from tumors. We aimed to determine if high-quality proteomics data could also be obtained from the remaining material. Here, we investigated procedures for generating deep and quantitatively accurate proteomic information in high throughput from Qiagen AllPrep flowthroughs. With a number of refinements, we obtain in excess of 10,000 quantified proteins, from 60 samples per day, achieving a substantial coverage of the total proteome. Additionally, we successfully characterize the tumors using phosphoproteomics. Combining a standard kit with in-depth proteomics will be an attractive approach for clinics seeking to implement multi-omics-based precision oncology.

Similar Papers

biorxiv
Thu May 08 2025
Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes
As cancer cell specific rewiring of metabolic networks creates potential therapeutic opportunities, we conducted a synthetic lethal screen utilizing inhibitors of metabolic pathways. Simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of ovarian cancer cells, but not of their non-oncogenically transformed progenitor cells. While (R)-GNE-140 i...
Dreute, J.
•
Stengel, J.
•
Becher, J.
•
van den Borre, D. R.
...•
Schmitz, M. L.
biorxiv
Thu May 08 2025
Loss of ATG5 expression in a subset of human prostate cancers promotes tumor growth through accumulation of p62
Loss-of-function mutations in autophagy-related (ATG) genes are rare in cancer. However, we report herein that ATG5 is fully deleted in ~14% of prostate cancers (PCa), rivaling that of well-established tumor suppressor genes. ATG5 expression was downregulated at both mRNA and protein levels and was associated with poor patient survival. The DU145 PCa cell line, isolated from a brain metastasis, is...
Wible, D. J.
•
Li, W.
•
Liu, X.
•
Sebastian, M. M.
...•
Bratton, S. B.
biorxiv
Thu May 08 2025
WITHDRAWN: Oncostratifier: Stratifying Oncogene-addicted Cohorts By Drug Response
Oncogenes, when mutated or overexpressed, drive tumorigenesis and can lead to oncogene addiction, where cancer cells rely on such genes for survival and proliferation. Stratifying oncogene-addicted cohorts is essential to uncover alternative therapeutic avenues, for instance in cases of untargetable oncogenes or resistance to treatment. We propose Oncostratifier, a framework to identify drugs that...
Tepeli, Y. I.
•
Trastulla, L.
•
Goncalves, J. P.
•
Iorio, F.
biorxiv
Thu May 08 2025
Hypomethylating agents induce epigenetic and transcriptional heterogeneity with implications for AML cell self-renewal.
DNA hypomethylating agents (HMAs) are used to treat acute myeloid leukemia (AML) and myelodysplasia patients who are unsuitable for intensive chemotherapy. However, low response rates and therapy-resistant relapse remain significant challenges. To improve outcomes, we must understand how AML cells survive HMA treatment and continue to proliferate following therapy. We combine single-cell multiomic...
Bond, D. R.
•
Burnard, S. M.
•
Uddipto, K.
•
Hunt, K. V.
...•
Lee, H. J.
biorxiv
Thu May 08 2025
Metabolic modulation of intratumoral cholesterol with gut microbiota for the treatment of colorectal cancer
Excess cholesterol is positively correlated with colorectal cancer (CRC). Current therapeutic strategies for modulating cholesterol levels in CRC are limited and often come with complications. Here, we demonstrated that microbiome shunting of intestinal cholesterol to anticancer metabolites is a safe and applicable therapeutic approach for CRC. By screening major microbial metabolic products of ch...
Wu, J.
•
Lai, Y.
•
Li, J.
•
Zhai, L.
...•
Wong, H. L. X.
biorxiv
Thu May 08 2025
Plasma Exosomes in Insulin Resistant Obesity Exacerbate Progression of Triple Negative Breast Cancer
Breast cancer, the most common cancer among women worldwide, continues to pose significant public health challenges. Among the subtypes of breast cancer, triple-negative breast cancer (TNBC) is particularly aggressive and difficult to treat due to the absence of receptors for estrogen, progesterone, or human epidermal growth factor receptor 2, rendering TNBC refractory to conventional targeted the...
Llevenes, P.
•
Chen, A.
•
Lawton, M. L.
•
Rondon-Ortiz, A. N.
...•
Denis, G. V.
biorxiv
Wed May 07 2025
Miro1 knockout inhibits mouse breast cancer tumorigenesis
Miro1 is a mitochondrial outer membrane protein that regulates mitochondrial and peroxisome trafficking, endoplasmic reticulum (ER) association, and mitophagy. Prior studies suggest a role for Miro1 in cell migration and proliferation in both normal and tumor cells. High Miro1 expression is associated with poor overall survival in breast cancer patients. To investigate the role of Miro1 in breast ...
Termos, R.
•
Muskat, A.
•
Shannon, N.
•
McCoy, M.
...•
Cunniff, B.
biorxiv
Wed May 07 2025
IRE1α and IRE1β Protect Intestinal Epithelium and Suppress Colorectal Tumorigenesis through Distinct Mechanisms
Intestinal epithelial cells (IECs) uniquely express two IRE1 paralogues, IRE1 and IRE1{beta}, whose roles in intestinal physiology are incompletely understood. We examined the individual and cooperative functions of IRE1 and IRE1{beta} in IECs using mice using intestine-specific deletion of Ire1 or germline Ire1{beta} deletion, and subsequently with double deleted Ire1, Ire1{beta} mice. At baselin...
Deng, R.
•
Wang, M.
•
Promlek, T.
•
Druelle-Cedano, C.
...•
Kaufman, R. J.
biorxiv
Wed May 07 2025
Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growth
Diffuse infiltrating gliomas are aggressive tumors of the central nervous system driven by intra-tumoral heterogeneity and aberrant normal-tumor cell-cell interactions. Grade specific and locoregional metabolic dependencies driving aberrant cell-states linked to treatment resistance, seizures and infiltration of gliomas remain elusive. Here, we applied spatial transcriptomics (stRNAseq), imaging m...
Ma, Y.
•
Ayadhury, S.
•
Singh, S.
•
Vashishath, Y.
...•
Ene, C. I.
biorxiv
Wed May 07 2025
Insights into gallbladder cancer pathogenesis from a living organoid gallbladder cholangiocyte biorepository
Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. Gallbladder cholangiocyte organoids (GCOs) or gallbladder carcinoma organoids (GBCOs) were developed and serially propagated from surgically resected gallbladder tissues with benign or malignant diseases, respectively. Patient derived organoids (PDOs) were derived from 15 normal...
Dutta, A.
•
Chowdhury, N.
•
Selvarajan, A. V.
•
Banerjee, P.
...•
GuhaSarkar, D.